<DOC>
	<DOCNO>NCT02274285</DOCNO>
	<brief_summary>Primary objective : - To demonstrate non-inferiority term seroprotection rate ( Hib antigen ( PRP ) , Diphtheria , Tetanus , Pertussis antigens ( PT FHA ) , polio type 1 , 2 3 antigen ) investigational arm ( Group A : DTaP-IPV/Hib ) versus control arm ( Group B : DTaP-IPV Hib vaccine administer separate site ) , one month primary vaccination ( antigen ) . Secondary objective : - To describe immune response vaccine antigens pre-specified hypothesis , time point ( pre-dose 1 , post-dose 3 , pre-dose 4 post-dose 4 ) two study group ( Group A Group B ) . - To describe safety dose vaccine two study group ( Group A Group B ) . - To describe immune response vaccine antigens pre-specified hypothesis , time point ( pre-dose 1 , post-dose 3 , pre-dose 4 post-dose 4 ( Group C )</brief_summary>
	<brief_title>DTaP-IPV/Hib Vaccine Primary &amp; Booster Vaccinations Versus Co-administration DTaP-IPV Hib Vaccine Japanese Infants</brief_title>
	<detailed_description>Participants enrol two step ( Cohort 1 Cohort 2 ) . Step one enroll Cohort 1 make 40 participant randomize two group 1:1 ratio . After review local systemic adverse event occur 7 Days follow first dose administer subject , 2nd vaccination Cohort 1 participant resume enrollment participant Cohort number 2 start . Step two enroll Cohort 2 make subject randomize two group 1:1 ratio . A sub-study Group C enrol receive vaccine intramuscular route .</detailed_description>
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Whooping Cough</mesh_term>
	<mesh_term>Tetanus</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Poliomyelitis</mesh_term>
	<mesh_term>Meningitis , Bacterial</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Aged 2 month 68 month inclusive ( recommend 3 8 month Groups A B ; 2 month Group C ) day inclusion Informed consent form sign parent ( ) legal representative Able attend schedule visit comply trial procedure . Fever ≥ 37.5°C ( axillary temperature ) day inclusion Any serious disease whether acute chronic Past current medical history GuillainBarre syndrome , acute thrombocytopenic purpura encephalopathy History diphtheria , tetanus , pertussis , poliomyelitis Haemophilus influenzae type b infection History life threaten reaction vaccine contain substance study vaccine History anaphylaxis study vaccine component Previous vaccination diphtheria , tetanus , pertussis , poliomyelitis Haemophilus influenzae type b infection trial vaccine another vaccine Congenital current acquire immunodeficiency , immunosuppressive therapy longterm systemic corticosteroid therapy Participation another clinical trial precede trial inclusion Planned participation another clinical trial present trial period Blood bloodderived product receive past current plan administration trial ( include immunoglobulin ) Any vaccination live vaccine within past 27 day precede first trial vaccination Any vaccination inactivate vaccine within past 6 day precede first trial vaccination Clinical known serological evidence systemic illness include Hepatitis B , Hepatitis C and/or HIV infection Subject ineligible accord Investigator 's clinical judgment Identified employee Investigator study center , direct involvement propose study study direction investigator study center , well family member ( i.e. , immediate , husband , wife child , adopt natural ) employee Investigator .</criteria>
	<gender>All</gender>
	<minimum_age>2 Months</minimum_age>
	<maximum_age>68 Months</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Tetanus</keyword>
	<keyword>Diphtheria</keyword>
	<keyword>Pertussis</keyword>
	<keyword>Poliomyelitis</keyword>
	<keyword>Bacterial meningitis</keyword>
	<keyword>DTaP-IPV/Hib Combination vaccine</keyword>
</DOC>